01/06/2026 17:07
Siemens and NVIDIA Expand Partnership to Build the Industrial AI Operating System

CES 2026 - Siemens and NVIDIA today announced a significant expansion of their strategic partnership to bring artificial intelligence into the real world. Together, the companies aim to develop industrial and physical AI solutions that will bring AI-driven innovation to every industry and industrial workflow, as well as accelerate each others’ operations. To support development, NVIDIA will provide AI infrastructure, simulation libraries, models, frameworks and blueprints, while Siemens will ...

01/06/2026 17:00
Siemens Unveils Technologies to Accelerate the Industrial AI Revolution at CES 2026

At CES 2026, Siemens’ keynote marked a new era of technology for industry and infrastructure, showcasing how customers and partners are harnessing artificial intelligence to transform their businesses. With AI-enabled technologies, deep domain expertise, and trusted partnerships, Siemens is converting this technological leap into measurable benefits for customers, partners, and society. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/2...

01/06/2026 17:00
Quectel Debuts Innovative SRG091X and SRG093X NXP i.MX Based Series Modules with Wi-Fi 6, Redefining Entry-level Processing for Next-generation IoT Applications

Quectel Wireless Solutions, a global end-to-end IoT solutions provider, today unveiled its SRG091X and SRG093X series modules at CES in Las Vegas, delivering integrated CPU, memory and wireless connectivity built around the NXP® Semiconductors i.MX 9 series of applications processors. This new generation of modules is engineered for industrial environments demanding high levels of automation, as well as consumer applications that require high data throughput and advanced multimedia capabiliti...

01/06/2026 18:30
ZIIHERA Plus TEVIMBRA and Chemotherapy: A Potential New Standard for First-Line HER2+ Advanced GEA

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced full results from the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), a HER2-targeted bispecific antibody, in combination with chemotherapy, with and without PD-1 inhibitor TEVIMBRA® (tislelizumab), as a first-line treatment for HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). These data, including the first interim overall survival ...

01/06/2026 19:00
Chemelex Adds Electric Heat Trace Group Ltd.’s SmartTrace Monitoring Platform to its Heat Tracing Portfolio

Chemelex, a global leader in electric thermal and sensing solutions, today announced the successful completion of its acquisition of substantially all the assets and ongoing operations of Electric Heat Trace Group Ltd. (EHT Group), headquartered in Ontario, Canada. This strategic move marks an exciting start to the new year and reinforces Chemelex’s commitment to delivering smarter, data-driven solutions for industrial heat trace systems. EHT Group is a recognized innovator in heat trace mana...

01/06/2026 19:35
SPIE, the International Society for Optics and Photonics, Announces Its 2026 Fellows

SPIE, the international society for optics and photonics, welcomes 40 Members as new Fellows of the Society in the 2026 cohort. They join their Fellow Member colleagues in being honored for their excellent technical achievements, as well as for their substantial service to the optics and photonics community and to SPIE. Fellows are Members of the Society who have made significant scientific and technical contributions in the multidisciplinary fields of optics, photonics, and imaging. Since the ...

01/06/2026 20:00
Brenus Pharma Reports Favorable Tolerability and Clinical Signals in Early Preliminary Results of First-In-Human Study for STC-1010 in Unresectable Metastatic Stage Colorectal Cancer (MSS CRC) Patients

Brenus Pharma, a clinical stage biotechnology company unlocking the immune system in vivo to fight solid tumors, announced the successful completion of the first dose levels in its ongoing first-in-human study. The multi-center, open-label trial (NCT06934538) is a phase Ia/Ib study designed to evaluate safety, tolerability and preliminary clinical activity of STC-10101 in a first line setting. It will include in vivo analysis of immune and tumor dynamics during dose escalation of treatment an...